Printer Friendly

UNIMED SIGNS AGREEMENT TO MARKET NEW PRODUCT LINE FOR SUPPORTIVE CARE OF HIV, AIDS AND CANCER PATIENTS

 UNIMED SIGNS AGREEMENT TO MARKET NEW PRODUCT LINE
 FOR SUPPORTIVE CARE OF HIV, AIDS AND CANCER PATIENTS
 SOMMERVELLE, N.J., Jan. 27 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) announced today that it has signed an agreement to market a new product line for supportive care of HIV, AIDS and cancer patients. Initial product introduction is scheduled for February.
 The product line, which will be trademarked "UNIMIST," is used in acute care of dry mouth (xerostomia), a significant side effect in HIV and AIDS patients as well as in cancer patients undergoing certain radiation and chemotherapies. Studies demonstrate that up to 80 percent of HIV patients and up to 90 percent of AIDS patients suffer from oral alterations including dry mouth. Cancer patients with dry mouth include 70 percent of the 120,000 head and neck cancer patients undergoing radiation therapy as well as 15 percent of the 150,000 lymphoma patients according to industry estimates. UNIMIST products are designed to replace the natural moisture in the mouth with an effective combination of electrolytes.
 "The introduction of this new product line is a major step in the continued development of our business," said Harold J. Tenoso, Ph.D., UNIMED's chairman and chief executive officer. "Active promotion by the UNIMED sales force should allow us to achieve a significant position in the market while expanding our distribution network in preparation for subsequent product introductions."
 UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer patients and AIDS patients.
 -0- 1/27/92
 /CONTACT: Charles P. Harrison, president of UNIMED, 908-526-6894/
 (UMED) CO: UNIMED, Inc. ST: New Jersey IN: MTC SU: PDT


JT -- NY007 -- 3570 01/27/92 09:16 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1992
Words:286
Previous Article:AMYLIN PHARMACEUTICALS INC. ANNOUNCES NOTICE OF PATENT ALLOWANCE
Next Article:TORONTO GROWTH CAUSES ACC TO DOUBLE CALL PROCESSING CAPACITY
Topics:


Related Articles
UNIMED SIGNS LICENSE AGREEMENT FOR DISTRIBUTION OF MARINOL IN SOUTH KOREA
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
GOVERNMENT CONTRACT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO FORMULATE CANCER AND AIDS DRUGS
UNIMED TO REGAIN CANADIAN MARKETING RIGHTS FOR MARINOL
UNIMED REPORTS PROCEEDS OF $9.26 MILLION FROM WARRANT EXERCISE
UNIMED PHARMACEUTICALS ANNOUNCES APPOINTMENT OF PRESIDENT/CEO
Unimed Announces Approval And Launch Of Marinol In South Africa
Unique Approach to Help Chronic Disease Sufferers Regain Strength and Restore Energy Now Available from Unimed Pharmaceuticals

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters